The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has announced it is assessing new data on the potential risk of neurodevelopmental disorders (NDDs) in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback